<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">There is a notorious concern regard the medicine administered to fight these comorbidities because some of them can lead to greater expression of ACE2, such as treatments for diabetes
 <xref rid="b0240" ref-type="bibr">
  <sup>48</sup>
 </xref> or hypertension.
 <xref rid="b0250" ref-type="bibr">
  <sup>50</sup>
 </xref> This may favour or even aggravate COVID-19 infection. These facts justify the urgency of research that contemplate alternative therapeutic targets such as calcium channels blockers for hypertensive individuals as suggested by Fang et al.
 <xref rid="b0240" ref-type="bibr">
  <sup>48</sup>
 </xref> However, there is little clinical evidence on the risk of treating COVID-19 patients with therapies that induce greater expression of ACE2. Further investigation is necessary to explore whether these medicines inhibit or trigger the viral entry into the cells of an infected host.
 <xref rid="b0255" ref-type="bibr">
  <sup>51</sup>
 </xref>
</p>
